These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26344890)

  • 1. Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.
    Kidokoro M; Shida H
    Vaccines (Basel); 2014 Oct; 2(4):755-71. PubMed ID: 26344890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice.
    Yokote H; Shinmura Y; Kanehara T; Maruno S; Kuranaga M; Matsui H; Hashizume S
    Vaccine; 2015 Nov; 33(45):6112-9. PubMed ID: 26241947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.
    Kidokoro M; Tashiro M; Shida H
    Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4152-7. PubMed ID: 15753319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate.
    Okamura T; Someya K; Matsuo K; Hasegawa A; Yamamoto N; Honda M
    Microbiol Immunol; 2006; 50(12):989-1000. PubMed ID: 17179668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.
    Meseda CA; Mayer AE; Kumar A; Garcia AD; Campbell J; Listrani P; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Clin Vaccine Immunol; 2009 Sep; 16(9):1261-71. PubMed ID: 19605597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox.
    Saijo M; Ami Y; Suzaki Y; Nagata N; Iwata N; Hasegawa H; Ogata M; Fukushi S; Mizutani T; Sata T; Kurata T; Kurane I; Morikawa S
    J Virol; 2006 Jun; 80(11):5179-88. PubMed ID: 16698998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of the vaccinia virus LC16m8Δ vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol.
    Sato H; Jing C; Isshiki M; Matsuo K; Kidokoro M; Takamura S; Zhang X; Ohashi T; Shida H
    Vaccine; 2013 Aug; 31(35):3549-57. PubMed ID: 23731631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
    Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
    Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
    J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.
    Morikawa S; Sakiyama T; Hasegawa H; Saijo M; Maeda A; Kurane I; Maeno G; Kimura J; Hirama C; Yoshida T; Asahi-Ozaki Y; Sata T; Kurata T; Kojima A
    J Virol; 2005 Sep; 79(18):11873-91. PubMed ID: 16140764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Serial Passage on the Pathogenicity and Immunogenicity of Vaccinia Virus LC16m8 Strain.
    Eto A; Yamamoto N; Kanatani Y
    Biology (Basel); 2021 Nov; 10(11):. PubMed ID: 34827150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological responses in humans to the smallpox vaccine LC16m8.
    Johnson BF; Kanatani Y; Fujii T; Saito T; Yokote H; Smith GL
    J Gen Virol; 2011 Oct; 92(Pt 10):2405-2410. PubMed ID: 21715598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosylated and nonglycosylated complement control protein of the lister strain of vaccinia virus.
    Meseda CA; Kuhn J; Atukorale V; Campbell J; Weir JP
    Clin Vaccine Immunol; 2014 Sep; 21(9):1330-8. PubMed ID: 25030055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of newly constructed attenuated vaccinia strain LC16m8Delta that expresses SIV Gag protein.
    Suzuki H; Kidokoro M; Fofana IB; Ohashi T; Okamura T; Matsuo K; Yamamoto N; Shida H
    Vaccine; 2009 Feb; 27(7):966-71. PubMed ID: 19135118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS; Earl PL; Eller LA; Moss B
    Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.